about
Arylthioamides as H2S Donors: l-Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in VivoPhenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors.Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma.Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection.TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance.Structure-activity relationship refinement and further assessment of 4-phenylquinazoline-2-carboxamide translocator protein ligands as antiproliferative agents in human glioblastoma tumors.Modulation of A2B adenosine receptor by 1-Benzyl-3-ketoindole derivatives.Allosteric modulators of human A2B adenosine receptor.3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A₂B adenosine receptor antagonists.Deepening the Topology of the Translocator Protein Binding Site by Novel N,N-Dialkyl-2-arylindol-3-ylglyoxylamidesBenzofuroxane Derivatives as Multi-Effective Agents for the Treatment of Cardiovascular Diabetic Complications. Synthesis, Functional Evaluation, and Molecular Modeling StudiesStudies on enantioselectivity of chiral 4-acetylamino-6-alkyloxy-2-alkylthiopyrimidines acting as antagonists of the human A adenosine receptorNovel 2-substituted-benzimidazole-6-sulfonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IX and XII and molecular docking studies
P50
Q35181925-F9527E78-F3F8-4834-AAA7-65EBE299FF61Q37695391-0E0CF8C5-8649-4540-97E0-6A5987E3E03BQ37718142-78740753-4256-4E75-9099-72E8F18E01B2Q38628896-0C343A4C-C44C-4EA7-80F0-5D97505A8D6FQ38938735-277269C8-D997-4C04-9F19-9FA9E8392AE5Q39020023-EEB5B4F5-F13E-4F7A-A693-F787984E9720Q44283724-EEA917ED-C590-467F-82E1-14566613A6D8Q45227053-7D0132D3-99EE-4D06-86B6-94E890C03EEDQ51761799-6483127F-B2BD-4FEC-867B-1F43053EA808Q58855652-9285C188-4E6D-47B5-B4C7-655C8C60B5B0Q58855699-F60C340E-DD22-4D1F-A5E0-EDDEC0264A2BQ58856016-F707B1AE-094E-40EE-86F0-394ED682F22AQ90180795-D77E7A44-C068-47A5-9168-90F227B0FA35
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-9814-7195
@en
name
Elisabetta Barresi
@ast
Elisabetta Barresi
@en
Elisabetta Barresi
@es
Elisabetta Barresi
@nl
type
label
Elisabetta Barresi
@ast
Elisabetta Barresi
@en
Elisabetta Barresi
@es
Elisabetta Barresi
@nl
prefLabel
Elisabetta Barresi
@ast
Elisabetta Barresi
@en
Elisabetta Barresi
@es
Elisabetta Barresi
@nl
P106
P1153
55861196300
P21
P31
P496
0000-0002-9814-7195